Geisinger precision health alums join virtual genetic care company

Genome Medical, a startup offering genomics-driven telehealth services with investors including Kaiser Permanente Ventures, added three alumni of Danville, Pa.-based Geisinger’s National Precision Health initiative to its leadership team.

Advertisement

Huntington Willard, PhD, founding director of Geisinger National Precision Health, has been appointed chief scientific officer and senior vice president of medical affairs for Genomic Medical.

“Genome Medical’s business needs as a leading medical practice and telegenomics company align well with my expertise in developing and operating precision health initiatives,” Dr. Willard said in a Jan. 23 news release. “I look forward to working with Lisa [Alderson, co-founder and CEO,] and the team to transform the way hospitals and health systems utilize population genomics programs to improve the quality of clinical care.”

Additionally, Erica Ramos, former director and head of clinical and product development for the Geisinger initiative, will serve as the startup’s vice president of population genomics, while Beth Denne, an associate professor and program leader in genetic counseling and education at the Geisinger program, has been tapped as director of education and engagement.

More articles on health IT:
Epic distancing itself from Google Cloud integrations & 13 other health IT notes
Former Cerner employees sue company over retirement plan fees
Apple VP says skepticism of big tech in healthcare is ‘healthy’

Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit

Advertisement

Next Up in Health IT

Advertisement

Comments are closed.